Diaceutics (LON:DXRX) Insider Purchases £150 in Stock

Diaceutics PLC (LON:DXRX) insider Jordan Clark bought 100 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were bought at an average cost of GBX 150 per share, for a total transaction of £150.

Jordan Clark also recently made the following trade(s):

• On Tuesday, December 23rd, Jordan Clark bought 117 shares of Diaceutics stock. The stock was bought at an average price of GBX 128 per share, for a total transaction of £149.76.

Diaceutics Price Performance

LON DXRX opened at GBX 144 on Thursday. The firm’s fifty day simple moving average is GBX 153.09 and its two-hundred day simple moving average is GBX 151.84. The firm has a market capitalization of £121.86 million, a P/E ratio of -80.00 and a beta of 0.58. The company has a current ratio of 3.96, a quick ratio of 9.92 and a debt-to-equity ratio of 3.05. Diaceutics PLC has a 12-month low of GBX 106 and a 12-month high of GBX 176.25.

Analysts Set New Price Targets

Separately, Shore Capital Group lifted their target price on Diaceutics from GBX 180 to GBX 215 and gave the stock a “buy” rating in a report on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Diaceutics currently has a consensus rating of “Buy” and an average target price of GBX 193.33.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.